Primary IOL implantation is successful in children under 2 years of age

Article

The implantation of intraocular lenses (IOL) is a safe and effective option for visual rehabilitation in children under 2 years of age, according to findings published in the British Journal of Ophthalmology.

The implantation of intraocular lenses (IOL) is safe and effective option for visual rehabilitation in children under 2 years of age, according to findings published in the British Journal of Ophthalmology.

Dr Ramesh Kekunnaya et al., Jasti V Ramanamma Children's Eye Care Center, Hyderabad, India, collected data from 120 eyes of 80 children with congenital/developmental cataract who underwent surgery between January 2006 and December 2007. Of the 120 eyes, 31 were operated on before they were 6 months of age and 89 eyes were operated on after 6 months of age. Rigid polymethylmethacrylate lenses were implanted in 30 eyes and acrylic hydrophobic foldable lenses were implanted in 90 eyes.

Five eyes demonstrated increased anterior chamber inflammation, 8 eyes experienced opacification of the visual axis, 2 eyes had decentration of IOL, 4 eyes experienced pigment dispersion on IOL and posterior synechiae were recorded in 5 eyes.

At the last follow-up there were no cases of glaucoma and no cases of endophthalmitis and retinal detachment. It was concluded that the implantation of IOLs in children below 2 years of age is a viable method for visual performance enhancement.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.